Clinical Studies

A Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine* for the potential treatment of chorea in patients with Huntington disease (HD).

A Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of valbenazine* in patients with dyskinetic cerebral palsy (DCP).

A Phase 1 study of investigational NBI-1076986 for the potential treatment of movement disorders.

A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of investigational NBI-921352 as an adjunctive therapy in children and young adults (2 to 21 years old) living with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).

A global, registrational, Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and tolerability of investigational crinecerfont in children and adolescents (2 to 17 years old) with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).

A global, registrational, Phase 3, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and tolerability of investigational crinecerfont in adults (18 years and older) with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD).

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine* as an add-on treatment for schizophrenia.

A Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of investigational NBI-1065845 in patients with inadequate responses to treatment in major depressive disorder (MDD).

A Phase 2, multicenter, multi-stage inpatient study to assess the efficacy, safety, tolerability, and pharmacokinetics of investigational NBI-1117568 in adults with schizophrenia.

A Phase 2 study of investigational NBI-1070770 for the treatment of major depressive disorder.

A Phase 1 study of investigational NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions.

A Phase 1 study of investigational NBI-1117569 for the potential treatment of certain neurological and neuropsychiatric conditions.

A Phase 1 study of investigational NBI-1065890 for the potential treatment of certain neurological and neuropsychiatric conditions.

A Phase 1 study of investigational NBI-1117567 for the potential treatment of certain neurological and neuropsychiatric conditions.